Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.

"CONFLICT OF INTEREST A.F. is a study investigator and an external study consultant who has served as an advisor for AbbVie, and a consultant for Abbott, UCB Pharma, Medtronic, Boston Scientific, and AbbVie. He has received research support from Medtronic, Boston Scientific, University of Toronto, Michael J. Fox Foundation for Parkinson's Research, and honoraria for serving as a speaker from UCB, Medtronic, Novartis, Chiesi, Boston Scientific, AbbVie, and Teva. V.S.C.F. receives a salary from NSW Health. He has received unrestricted research grants from AbbVie and Merz; is on advisory boards and/or has received travel grants from AbbVie, Allergan, Cavion, Ipsen, Merz, Praxis, Seqirus, Stada, Teva, and UCB; and receives royalties from Health Press Ltd. K.S. reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal, Stada, Licher Pharma, Biogen, BIAL and AbbVie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and AOP Orphan Pharmaceuticals AG, outside the submitted work. Z.P. was a study investigator and has received compensation from AbbVie for speaker‐related activities. A.T. was a study investigator and has served as an advisor for AbbVie. She has also served as a consultant for UCB pharma, Ever Pharma, TEVA, and AbbVie, and has received honoraria from UCB, MERZ, AbbVie, and Teva for serving as speaker. A.A., K.O., L.B., and J.C.P. are employees of AbbVie and may hold AbbVie stock and/or stock options. B.E. was a study investigator, has served as a local advisor for AbbVie, and has received honoraria from AbbVie for serving as a speaker."

"Funding information"